Premium
Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview
Author(s) -
Delaby Constance,
Teunissen Charlotte E.,
Blennow Kaj,
Alcolea Daniel,
Arisi Ivan,
Amar Elodie Bouaziz,
Beaume Anne,
Bedel Aurélie,
Bellomo Giovanni,
BigotCorbel Edith,
Bjerke Maria,
BlancQuintin MarieCéline,
Boada Mercè,
Bousiges Olivier,
Chapman Miles D,
DeMarco Mari L.,
D'Onofrio Mara,
Dumurgier Julien,
DufourRainfray Diane,
Engelborghs Sebastiaan,
Esselmann Hermann,
Fogli Anne,
Gabelle Audrey,
Galloni Elisabetta,
Gondolf Clémentine,
Grandhomme Frédérique,
GrauRivera Oriol,
Hart Melanie,
Ikeuchi Takeshi,
Jeromin Andreas,
Kasuga Kensaku,
Keshavan Ashvini,
Khalil Michael,
Körtvelyessy Peter,
KulczynskaPrzybik Agnieszka,
Laplanche JeanLouis,
Lewczuk Piotr,
Li QiaoXin,
Lleó Alberto,
Malaplate Catherine,
Marquié Marta,
Masters Colin L.,
Mroczko Barbara,
Nogueira Léonor,
Orellana Adelina,
Otto Markus,
Oudart JeanBaptiste,
Paquet Claire,
Paoletti Federico Paolini,
Parnetti Lucilla,
PerretLiaudet Armand,
Peoc'h Katell,
Poesen Koen,
PuigPijoan Albert,
Quadrio Isabelle,
QuillardMuraine Muriel,
Rucheton Benoit,
Schraen Susanna,
Schott Jonathan M.,
Shaw Leslie M.,
SuárezCalvet Marc,
Tsolaki Magda,
Tumani Hayrettin,
UdehMomoh Chinedu T,
Vaudran Lucie,
Verbeek Marcel M,
Verde Federico,
Vermunt Lisa,
Vogelgsang Jonathan,
Wiltfang Jens,
Zetterberg Henrik,
Lehmann Sylvain
Publication year - 2022
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.12545
Subject(s) - context (archaeology) , biomarker , cerebrospinal fluid , disease , medicine , intensive care medicine , interpretation (philosophy) , pathology , computer science , biology , paleontology , biochemistry , programming language
The current practice of quantifying cerebrospinal fluid (CSF) biomarkers as an aid in the diagnosis of Alzheimer's disease (AD) varies from center to center. For a same biochemical profile, interpretation and reporting of results may differ, which can lead to misunderstandings and raises questions about the commutability of tests. Methods We obtained a description of (pre‐)analytical protocols and sample reports from 40 centers worldwide. A consensus approach allowed us to propose harmonized comments corresponding to the different CSF biomarker profiles observed in patients. Results The (pre‐)analytical procedures were similar between centers. There was considerable heterogeneity in cutoff definitions and report comments. We therefore identified and selected by consensus the most accurate and informative comments regarding the interpretation of CSF biomarkers in the context of AD diagnosis. Discussion This is the first time that harmonized reports are proposed across worldwide specialized laboratories involved in the biochemical diagnosis of AD.